The disclosure includes novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacytidine is represented by the formula: ##STR00001## The disclosure also includes pharmaceutical compositions comprising said forms.